Abstract
There is a need for effective systemic therapy for central nervous system (CNS) hemangioblastomas (HBs). We report a case of erlotinib therapy for CNS HBs in a patient with von Hippel-Lindau disease, in whom the HBs were associated with diffuse leptomeningeal seeding. We provide the first report of paired serum and cerebrospinal fluid (CSF) levels of erlotinib while on standard dosing. The patient exhibited neurologic and imaging signs of recurrent CNS HBs and progressive leptomeningeal metastasis following surgery, radiation, and stereotactic radiosurgery. The patient was treated with erlotinib 150 mg daily. The patient achieved a minor response to erlotinib therapy, including clinical improvement, reduction in size of two enhancing brain lesions (one of which, however, proved at autopsy to be radiation necrosis) and stabilization of leptomeningeal enhancement. In addition, the CSF white count improved. The duration of response was 9 months. The median plasma and CSF levels of erlotinib while on treatment were 1146.06 and 247.83 ng/ml, respectively (CSF 21.6% of plasma). Erlotinib may have antitumor activity in CNS HBs.
This is a preview of subscription content, log in via an institution to check access.
References
Böhling T, Hatva E, Kujala M et al (1996) Expression of growth factors and growth factor receptors in capillary hemangioblastoma. J Neuropathol Exp Neurol 55:522–527
Reifenberger G, Reifenberger J, Bilzer T, Wolfgang W, Collins VP (1995) Coexpression of transforming growth factor-a and epidermal growth factor receptor in capillary hemangioblastomas of the central nervous system. Am J Pathol 147:245–250
Jagannathan J, Lonser RR, Smith R, DeVroom HL, Oldfield EH (2008) Surgical management of cerebellar hemangioblastomas in patients with von Hippel-Lindau disease. J Neurosurg 108:210–222
Kano H, Niranjan A, Mongia S et al (2008) The role of stereotactic radiosurgery for intracranial hemangioblastomas. Neurosurgery 63:443–451
Bakshi R, Mechtler LL, Patel MJ et al (1997) Spinal leptomeningeal hemangioblastomatosis in von Hippel-Lindau disease: magnetic resonance and pathological findings. J Neuroimaging 7:242–244
Reyns N, Assaker R, Louis E, Lejeune J-P (2003) Leptomeningeal hemangioblastomatosis in a case of von Hippel-Lindau disease: case report. Neurosurgery 52:1212–1216
Niemelä M, Mäenpää H, Salven P et al (2001) Interferon α-2a therapy in 18 hemangioblastomas. Clin Cancer Res 7:510–516
Aiello LP, George DJ, Cahill MT et al (2002) Rapid and durable recovery of visual function in a patient with von Hippel-Lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor SU5416. Ophthalmology 109:1745–1751
Girmens J-F, Erginay A, Massin P et al (2003) Treatment of von Hippel-Lindau retinal hemangioblastoma by the vascular endothelial growth factor receptor inhibitor SU5416 is more effective for associated macular edema than for hemangioblastomas. Am J Ophthalmol 136:194–196
Schuch G, de Wit M, Höltje J et al (2005) Hemangioblastomas: diagnosis of von Hippel-Lindau disease and antiangiogenic treatment with SU5416. J Clin Oncol 23:3624–3626
Madhusudan S, Deplanque G, Braybrooke JP et al (2004) Antiangiogenic therapy for von Hippel-Lindau disease (research letter). JAMA 291:943–944
Piribauer M, Dieckmann K, Birner P et al (2004) Stabilization of a progressive hemangioblastoma under treatment with thalidomide. J Neurooncol 66:295–299
Smith K, Gunaratnam L, Morley M et al (2005) Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL−/− renal cancer. Cancer Res 65:5221–5230
Park YS, Chang JH, Chang JW, Chung SS, Park YG (2005) Gamma knife surgery for multiple hemangioblastomas. J Neurosurg 102:97–101
Haas-Kogan DA, Prados MD, Tihan T et al (2005) Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 97:880–887
Vogelbaum MA, Nelms JL, Daneshvar H, Cutter CT, Gill S (2003) Evaluation of tissue penetration of Tarceva [OSI-774] in a rat xenograft brain tumor model (abstract). AACR-NCI-EORTC Symposium on Targeted Therapeutics
Broniscer A, Panetta JC, O’Shaughnessy M et al (2007) Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420. Clin Cancer Res 13:1511–1515
Buie LW, Lindley C, Shih T et al (2007) Plasma pharmacokinetics and cerebrospinal fluid concentrations of erlotinib in high-grade gliomas: a novel, phase 1, dose escalation study (abstract). Proc ASCO 25:88
Lassman AB, Rossi MR, Raizer JJ et al (2005) Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01–03 and 00–01. Clin Cancer Res 11:7841–7850
Acknowledgements
The authors thank Oliver Bögler, PhD, and Susan Finniss, MS, for measuring the VEGF levels and Susan Dorman, PhD, at MDS Pharma Services for measuring the drug concentrations.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rogers, L.R., LoRusso, P., Nadler, P. et al. Erlotinib therapy for central nervous system hemangioblastomatosis associated with von Hippel-Lindau disease: a case report. J Neurooncol 101, 307–310 (2011). https://doi.org/10.1007/s11060-010-0244-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-010-0244-3